Radha Agrawal, MD
Pulmonary Disease · Bellevue, WANPI 1881629798
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,375 of the $7,643 with a category attached, or 96.5%. Verathon Inc. accounts for 96.5% of it on its own, with 5 other manufacturers making up the rest.
Across 13 payments — averaging $587.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verathon Inc.$7K
- Pulmonx Corporation$146
- Sanofi-aventis U.S. LLC$57
- Abiomed$28
- Sanofi$20
- Insmed, Inc.$17
What the payments were for
- Consulting fees$7,37596%
- Food & beverage$1943%
- Education$751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Verathon Inc. | 8 | $7,375 |
| Pulmonx Corporation | 1 | $146 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Abiomed | 1 | $28 |
| Sanofi | 1 | $20 |
| Insmed, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bronchoscope$2,775
- B Flex$1,500
- Bronchoscope and Video Laryngoscope$1,250
- NPD Clinical Study$850
- HYDRA TEST$500
- BFLEX$500
- CHARTIS CATHETER$146
- ZEPHYR DELIVERY CATHETER$146
- ZEPHYR ENDOBRONCHIAL VALVE$146
- PULMONX CHARTIS TABLET CONSOLE$146
How this compares
$7,643 in reported general payments places this provider in the 85th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 270 | $243,023 |
| OfevNintedanib Esylate | 13 | $166,054 |
| Dupixent SyringeDupilumab | 24 | $90,481 |
| Breo ElliptaFluticasone/Vilanterol | 92 | $48,218 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 45 | $33,118 |
| Spiriva HandihalerTiotropium Bromide | 47 | $29,476 |
| Spiriva RespimatTiotropium Bromide | 42 | $21,256 |
| EliquisApixaban | 27 | $19,174 |
| DuleraMometasone/Formoterol | 28 | $12,354 |
| Advair HfaFluticasone Propion/Salmeterol | 18 | $9,769 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $8,209 |
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,867 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 142 | $4,024 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,886 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 21 | $3,594 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Bellevue
- Todd FreudenbergerBellevue$4K
- Saleh IsmailBellevue$4K
- Jed GordenSeattle$236K
- Dominique PepperOlympia$212K
- Jiten PatelSpokane$200K
- Oneil BainsSeattle$156K
- Ganesh RaghuSeattle$147K
- Nicholas WyshamVancouver$117K
- Colleen OverdorfBellingham$110K
- Jeffrey CarySeattle$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.